Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Implantable Microdevice for in Situ Evaluation of Drug Response in Primary Bladder Tumors
NCT06204614Phase 1Enrolling by invitation
- Sponsor
- Brigham and Women's Hospital
- Start
- Jun 2024
- Primary completion
- Jul 2028
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial, sponsored by Brigham and Women's Hospital. Primary endpoints: Safety of microdevice placement and removal based on assessment of adverse events at 6 weeks and Feasibility of microdevice placement at 48 hours. Started Jun 2024; status: enrolling by invitation.
Beyond the preview
Go deeper on NCT06204614.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06204614.